Evidence map›Paper›PMID 30555032›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2019

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia.

Rosalinde E R Slot, Sietske A M Sikkes, Johannes Berkhof, Henry Brodaty, Rachel Buckley, Enrica Cavedo, Efthimios Dardiotis, Francoise Guillo-Benarous, Harald Hampel, Nicole A Kochan and 25 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
218citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

218 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Minor neuropsychological deficits and stage 2 of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

158 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Rosalinde E R SlotAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
Sietske A M SikkesAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; Department of Epidemiology and Biostatistics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
Johannes BerkhofDepartment of Epidemiology and Biostatistics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
Henry BrodatyCenter for Healthy Brain Ageing and Dementia Centre for Research Collaboration, University of New South Wales, Sydney, Australia.
Rachel BuckleyUniversity of Melbourne, Melbourne, Australia; The Florey Institutes of Neurosciences and Mental Health, Melbourne, Australia; Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Enrica CavedoAXA Research Fund & Sorbonne University Chair, Paris, France; Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France; Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France; Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Efthimios DardiotisDepartment of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Francoise Guillo-BenarousNew York University Alzheimer's Disease Center, NYU Langone Medical Center, New York, NY, USA.
Harald HampelAXA Research Fund & Sorbonne University Chair, Paris, France; Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France; Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France; Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Nicole A KochanCenter for Healthy Brain Ageing and Dementia Centre for Research Collaboration, University of New South Wales, Sydney, Australia; Neuropsychiatric Institute, Prince of Wales Hospital, Randwick, Australia.
Simone ListaAXA Research Fund & Sorbonne University Chair, Paris, France; Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France; Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France; Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Tobias LuckInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Faculty of Medicine, University of Leipzig, Leipzig, Germany; Social Psychiatry, Department of Economic and Social Sciences, University of Applied Sciences Nordhausen, Nordhausen, Germany.
Paul MaruffThe Florey Institutes of Neurosciences and Mental Health, Melbourne, Australia; Cogstate Ltd., Melbourne, Australia.
José Luis MolinuevoNeurology Department, Hospital Clínic i Universitari-IDIBAPS and BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.
Johannes KornhuberFriedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Barry ReisbergNew York University Alzheimer's Disease Center, NYU Langone Medical Center, New York, NY, USA.
Steffi G Riedel-HellerInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Faculty of Medicine, University of Leipzig, Leipzig, Germany.
Shannon L RisacherCenter for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine Indianapolis, IN, USA; Indiana Alzheimer Disease Center, Indiana University School of Medicine Indianapolis, IN, USA.
Susanne RoehrInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Faculty of Medicine, University of Leipzig, Leipzig, Germany; LIFE - Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany.
Perminder S SachdevCenter for Healthy Brain Ageing and Dementia Centre for Research Collaboration, University of New South Wales, Sydney, Australia; Neuropsychiatric Institute, Prince of Wales Hospital, Randwick, Australia.
Nikolaos ScarmeasNational and Kapodistrian University of Athens, Athens, Greece; Department of Neurology, Columbia University Medical Center, New York, NY, USA.
Philip ScheltensAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
Melanie B ShulmanNew York University Alzheimer's Disease Center, NYU Langone Medical Center, New York, NY, USA.
Andrew J SaykinCenter for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine Indianapolis, IN, USA; Indiana Alzheimer Disease Center, Indiana University School of Medicine Indianapolis, IN, USA.
Sander C J VerfaillieAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
Pieter Jelle VisserAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.
Stephanie J B VosDepartment of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.
Michael WagnerDZNE, German Center for Neurodegenerative Diseases, Germany; Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
Steffen WolfsgruberDZNE, German Center for Neurodegenerative Diseases, Germany; Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
Frank JessenDZNE, German Center for Neurodegenerative Diseases, Germany; Psychiatry Department, University of Cologne, Cologne, Germany.
Alzheimer's Disease Neuroimaging Initiative
DESCRIPA working group
INSIGHT-preAD study group
SCD-I working group
Wiesje M van der FlierAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; Department of Epidemiology and Biostatistics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. Electronic address: wm.vdflier@vumc.nl.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
PSYCHOSOCIAL COREP30AG008051 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WISNIEWSKI, THOMAS M · 1990 to 2019
$36.1M
Memory Circuitry in MCI and Early Alzheimer’s Disease Prodrome: Molecular DriversR01AG019771 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 2001 to 2021
$6.9M
AGING AND DEMENTIA--LONGITUDINAL STUDYR01AG003051 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI REISBERG, BARRY · 1987 to 2002
$850k
Sensory and Perceptual Measures as Biomarkers of Alzheimer's Disease PathologyK01AG049050 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI RISACHER, SHANNON L · 2015 to 2019
$612k
NIA NIH HHS K01 AG049050NIA NIH HHS P30 AG008051NIA NIH HHS P30 AG010133NIA NIH HHS R01 AG003051NIA NIH HHS R01 AG019771NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

introductionIn this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression to dementia.

methodsEleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dementia incidence and identified risk factors using Cox proportional hazards models.

resultsIn SCD, incidence of dementia was 17.7 (95% Poisson confidence interval 15.2-20.3)/1000 person-years (AD: 11.5 [9.6-13.7], non-AD: 6.1 [4.7-7.7]), compared with 14.2 (11.3-17.6) in controls (AD: 10.1 [7.7-13.0], non-AD: 4.1 [2.6-6.0]). The risk of dementia was strongly increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, higher age (hazard ratio 1.1 [95% confidence interval 1.1-1.1]), lower Mini-Mental State Examination (0.7 [0.66-0.8]), and apolipoprotein E ε4 (1.8 [1.3-2.5]) increased the risk of dementia. DISCUSSION: SCD can precede both AD and non-AD dementia. Despite their younger age, individuals with SCD in a memory clinic setting have a higher risk of dementia than those in community-based cohorts.

Indexed as

AgedAged, 80 and overCognitive DysfunctionCohort StudiesDementiaDiagnostic Self EvaluationDisease ProgressionFemaleHumansIncidenceMaleMiddle AgedRisk FactorsSelf ConceptAlzheimer's diseaseDementia incidenceDementia Lewy bodiesFrontotemporal dementiaPreclinical Alzheimer's diseaseSubjective cognitive declineVascular dementia

Identifiers

PMID30555032
PMCPMC6465066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.